Stockreport

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF ARQ-255 is a topical Janus kinase 1 (JAK1) inhibitor suspension formulated as a potential topical treatment for alopecia areataProprietary Deep Dermal Drug Delivery (4D) [Read more]